2025 Year-End Themes, Part 2: The Two Things That Have to Change for Any of the Rest of It to Work

This is Part 2 of Stacey's year-end synthesis of the most actionable themes from 2025. Last week covered Themes 1–3. This week covers 4 and 5 — which are, if you squint, really two sides of the same problem: plan sponsors can't buy value when they can't see what they're buying, and they can't see what they're buying because the vendors who benefit from opacity are the ones controlling the data.

WHAT YOU'LL LEARN

✅ Theme 4 — Lack of transparency and data access allows wild overspending and undermines fiduciary duty: status quo TPAs, PBMs, and brokers routinely withhold essential claims data, creating "data hostage" situations that expose self-insured employers to both financial and legal risk — Elizabeth Mitchell from PBGH puts it directly: jumbo employers are spending over $350 billion a year on healthcare services and people's health is not improving, yet carriers are "remarkably resistant" to even sharing data their clients are legally entitled to under the CAA

✅ How the transparency gap plays out for members: patients with so-called good insurance now fear unexpected bills enough to delay or abandon necessary care — suspicious moles, chest pain, asthma inhalers — worsening long-term health outcomes in ways that compound costs downstream

✅ The hospital price and ownership transparency angle: up to 80% of hospital bills may contain errors; carrier spread pricing adds an estimated 30% on top of what hospitals actually charge; and without itemized bill access, plan sponsors have no way to know which part of their spend is going to clinicians vs. getting absorbed by intermediaries or health system administrative expansion

✅ Theme 5 — Shifting purchasing from discounts and volume to value: the healthcare cost flywheel is driven by buying discounts off inflated list prices — and as Mark Cuban describes it, the fix is direct contracting where providers get cash upfront, zero member deductible, zero collection risk, and zero prior auth denial risk; in return, the plan gets pricing at or near cash/Medicare rates

✅ What Sarah Emond explains about rebates vs. value: the rebate model rewards market dominance and discount size, not clinical outcomes — if payers paid value-based prices, prior auth requirements and cost sharing could largely disappear, and physicians could prescribe the drug that's actually best for the patient rather than the one that generated the best rebate negotiation

✅ Why self-insured employers are the demand curve — or there isn't one: 160 million Americans get coverage through self-insured employers; if those employers don't act as an elastic demand curve — meaning they stop buying from high-cost, low-value providers — there is no market incentive for anyone on the supply side to lower prices or improve quality; the market that everyone assumes is constraining healthcare costs does not exist without a demand curve

WHY THIS MATTERS

The one-star Spotify review Stacey received this year said this was an echo chamber for out-of-touch CEOs. Stacey's response: when employers shift purchasing to value and pay upfront at fair prices, clinicians get paid more, faster, with less administrative overhead. The interests are more aligned than they appear. The opacity is what keeps them from finding each other. Theme 4 and Theme 5 are not abstract policy goals — they are the infrastructure on which better outcomes, lower member costs, and sustainable clinical practice all depend.

=== LINKS ===
🔗  Show Notes with all mentioned links:  
https://cc-lnk.com/INBW45

✉️  Enjoy this podcast? Subscribe to the free weekly newsletter:
https://relentlesshealthvalue.com/join-the-relentless-tribe

🫙  Support the podcast with a small donation to the Tip Jar:
https://relentlesshealthvalue.com/join-the-relentless-tribe

🎤  Listen on Apple Podcasts  https://podcasts.apple.com/us/podcast/feed/id892082003?ls=1

🎤  Listen on Spotify  https://open.spotify.com/show/6UjgzI7bScDrWvZEk2f46b

📺  Subscribe to our YouTube channel   https://www.youtube.com/@RelentlessHealthValue

=== CONNECT WITH THE RHV TEAM ===
✭ LinkedIn   https://www.linkedin.com/company/relentless-health-value/
✭ Threads  https://www.threads.net/@relentlesshealthvalue/
✭ Bluesky   https://bsky.app/profile/relentleshealth.bsky.social
✭ X   https://twitter.com/relentleshealth/

00:00 Introduction

03:30 Theme 4: lack of transparency and data access.

04:46 Clip of Elizabeth Mitchell from EP436.

07:07 Is there a tipping point finally coming regarding transparency?

08:58 Why and how siloed data is also part of this transparency issue.

11:37 How opaque pricing leads to more opaque pricing.

13:21 The need for transparency around ownership and what that looks like in healthcare.

14:06 Theme 5: the need to shift purchasing from discounts/volume to value.

14:52 Clip of Mark Cuban from EP488.

16:35 Clip of Sarah Emond from EP494.

17:02 How pricing transparency can eliminate the need for rebates and prior authorizations.

18:30 Why healthcare needs a demand curve.

22:09 Shows covered in 2025 that touched on other timely ideas.